Premarket Movers: Apple Drops, Oracle Soars

Several major stocks are making waves in premarket trading today. Apple (NASDAQ:AAPL) saw a slight dip after the European Union's top court ruled against the company in a long-standing tax case related to its operations in Ireland. This comes just as the tech giant launched new AI-enhanced iPhones.

Meanwhile, Oracle (NYSE: ORCL) shares surged following strong first-quarter earnings that surpassed analysts’ expectations. The company's cloud services business was the key driver, and its new strategic partnership with Amazon Web Services (AWS) added to the positive momentum.

Oracle Shares Surge as Cloud Demand Fuels Stronger-Than-Expected Q1 Results and Strategic AWS Partnership >>

The Chinese e-commerce giant Alibaba (NYSE:BABA) gained after announcing its inclusion in the Southbound Connect, which links Hong Kong’s stock market with mainland exchanges. This move is seen as a win for the company, which recently upgraded its Hong Kong listing.

Boot Barn (NYSE:BOOT) shares jumped 6% after the Western-style retailer reported a 4% increase in consolidated same-store sales for its fiscal second quarter. This update came ahead of the company’s presentation at a Piper Sandler conference.

Not all companies are seeing gains, though. Data security firm Rubrik (NYSE:RBRK) dropped 8.2% after releasing second-quarter results that sparked concerns about its future fiscal performance.

In contrast, avocado distributor Mission Produce (NASDAQ:AVO) saw its shares jump thanks to better-than-expected third-quarter revenue, signaling strong demand.

Hewlett Packard Enterprise (NYSE:HPE) saw a significant drop of over 5% premarket. The decline came after HPE announced plans to raise $1.35 billion through a Series C mandatory convertible preferred stock offering. The proceeds will fund its acquisition of Juniper Networks.

Finally, Viridian Therapeutics (NASDAQ: VRDN) surged after announcing that its experimental treatment for thyroid eye disease showed significant reductions in eye inflammation in late-stage trials.